MPCs as a commodity. Bleeding obvious., page-2

@benelong

Brilliant mate. Ive stated before that MPC's are like millions of homing cells that find the damaged tissue. They just know where to go.

Attaching molecules to the tracking devices has huge potential.

Hence the partnership with Cartherics for cancer. They too need Mesoblast as well.

NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies.

https://globenewswire.com/news-rele...-based-Immunotherapies-for-Solid-Cancers.html